Translation – at the heart of what we seek to do
The UK continues to be among the best places in the world to develop, manufacture and sell therapies utilising the principles of regenerative medicine.
ecent initiatives such as the Advanced Therapies Taskforce – chaired by George Freeman, UK Minister for Life
Sciences and Ian McCubbin of GSK – have sought to examine the conditions and actions required to anchor Advanced Therapy (ATMP) manufacturing in the UK. As noted by Professor John Fisher in his Foreword, Regener8’s strategic focus is on regenerative devices as a further essential component of the UK’s regenerative medicine offering.
Regenerative devices – regenerative therapies that can be delivered to the market and the patient as Class III medical devices (or human tissue products) – are likely to be translated and adopted more rapidly than advanced therapies due to their device classification and lower overall risk rating. As such, they will be able to provide the quick(er) wins still needed by the regenerative medicine industry to verify the overall value proposition. Such wins are, however, close to realisation – with the translational achievements of Tissue Regenix, Azellon, Videregen, Cytori Therapeutics, Orthox, Locate Therapeutics, TiGenix, Osteopore, Neotherix, Xeltis, Organovo and NHS Blood and Transplant, for instance, making a non-exclusive roll of honour.
Regener8, together with its wider network partners at the Medical Technologies IKC in Leeds and across the UK, will continue to provide advice and sector-relevant examples, make connections and – through EPSRC and other funders – establish proof of concept (PoC) through collaborative projects for regenerative device applications. The UK has a rich pool of talent in academic, clinical and industry settings and it is vital that these are brought together – through themed workshops and conferences such as the Regener8 Annual Meeting (now in
its 9th year) – to share information and realise opportunities. We are looking forward to making new connections through this year’s meeting. We want to understand the particular barriers to translation experienced by our members (which is what we hope all connections will become) and together with our matrix of experts, help find solutions and the means to overcome these barriers.
For this year’s conference, Regener8 has restated its tagline to “Translating Regenerative Devices”. Translation is at the heart of what we seek to do: translational research must result in better, more effective, stratified and affordable products and treatments. We must not forget that the priority for the patient is for our research to be brought to them as effective treatments as soon as possible.
In this issue 7 of regen, you will find news of key players in the RegenMed landscape as well as case studies from PoC projects supported or assisted by Regener8 and the IKC. We have included a feature for the first time this year in which stakeholders occupying various roles and positions of responsibility give their assessment of the challenges and opportunities ahead for RegenMed. This makes for a fascinating commentary on the reasons for optimism and the work still to be done in our field.
Regener8 and its partners continue to recognise the need to both ensure a succession of skilled and appropriately trained people to enter the medical technology and regenerative medicine sectors at all levels and to create an interest, understanding and trust in what we do. We are therefore very pleased to include articles on public engagement and responsible innovation in this issue.
Through our positions of influence at numerous levels, Regener8 and the Medical Technologies IKC can provide advocacy, particularly for the regenerative device stream of the regenerative medicine sector. Our membership, events and programmes bring together the right players at the right level of engagement to strengthen the translation of regenerative devices.
Professor Mike Raxworthy Regener8 Operations Director
Regener8 and its partners continue to recognise the need to both ensure a succession of skilled and appropriately trained people to enter the medical technology and regenerative medicine sectors at all levels and to create an interest, understanding and trust in what we do.
We must not forget that the priority for the patient is for our research to be brought to them as effective treatments as soon as possible.
Through our positions of influence at numerous levels, Regener8 and the Medical Technologies IKC can provide advocacy particularly for the regenerative device stream of the regenerative medicine sector.
Mike Raxworthy Regener8 Operations Director
4 – 5
regen. Issue 7
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17